Elicio Therapeutics, Inc. Financials
Financial Health Signals
Elicio Therapeutics, Inc. passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Elicio Therapeutics, Inc. generates $0.71 in operating cash flow (-$37.1M OCF vs -$51.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Elicio Therapeutics, Inc. earns $-98.9 in operating income for every $1 of interest expense (-$45.0M vs $455K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Elicio Therapeutics, Inc. (ELTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Elicio Therapeutics, Inc.'s EBITDA was -$44.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 26.3% from the prior year.
Elicio Therapeutics, Inc. generated -$37.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 13.4% from the prior year.
Elicio Therapeutics, Inc. reported -$51.9M in net income in fiscal year 2024. This represents a decrease of 47.5% from the prior year.
Elicio Therapeutics, Inc. earned $-4.25 per diluted share (EPS) in fiscal year 2024. This represents an increase of 38.9% from the prior year.
Elicio Therapeutics, Inc. held $17.6M in cash against $20.0M in long-term debt as of fiscal year 2024.
Elicio Therapeutics, Inc. had 11M shares outstanding in fiscal year 2024. This represents an increase of 14.8% from the prior year.
Elicio Therapeutics, Inc. invested $33.7M in research and development in fiscal year 2024. This represents an increase of 41.1% from the prior year.
Elicio Therapeutics, Inc. spent $0 on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 100.0% from the prior year.
Elicio Therapeutics, Inc. invested $87K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 31.8% from the prior year.
ELTX Income Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $0 | $0 | $0-100.0% | $653K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.0M-30.1% | $7.2M | N/A | $7.3M+32.5% | $5.5M+271.5% | -$3.2M-169.6% | $4.6M-8.9% | $5.0M |
| SG&A Expenses | $3.0M-4.1% | $3.1M | N/A | $3.5M+51.1% | $2.3M+292.8% | -$1.2M-202.3% | $1.2M-1.2% | $1.2M |
| Operating Income | -$8.0M+22.2% | -$10.3M | N/A | -$10.8M-38.0% | -$7.8M-383.4% | $2.8M+147.7% | -$5.8M+7.4% | -$6.2M |
| Interest Expense | $426K+210.9% | $137K | N/A | $1K-99.7% | $342K-75.0% | $1.4M+26.7% | $1.1M+1.0% | $1.1M |
| Income Tax | $0 | $0 | N/A | $0 | $0 | N/A | $0 | $0 |
| Net Income | -$10.1M+46.5% | -$18.8M | N/A | -$10.7M-32.7% | -$8.0M-20.7% | -$6.7M+7.6% | -$7.2M+1.4% | -$7.3M |
| EPS (Diluted) | $-0.60+56.8% | $-1.39 | N/A | $-1.27 | $-24.77 | $-42.92 | $-22.67+2.3% | $-23.20 |
ELTX Balance Sheet
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $28.3M+0.4% | $28.2M+3.8% | $27.1M-12.4% | $31.0M-25.8% | $41.8M+84.3% | $22.7M-63.0% | $61.3M-13.4% | $70.8M |
| Current Assets | $21.5M+3.7% | $20.7M+26.6% | $16.3M-18.0% | $19.9M-50.9% | $40.6M+279.1% | $10.7M-81.1% | $56.7M-14.0% | $65.9M |
| Cash & Equivalents | $20.6M+17.0% | $17.6M+36.6% | $12.9M-13.1% | $14.8M+73.1% | $8.6M+39.2% | $6.2M+234.7% | $1.8M+207.5% | $598K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $24.5M-38.0% | $39.5M+150.4% | $15.8M-10.9% | $17.7M-88.3% | $151.6M+21.5% | $124.8M-20.5% | $157.0M-1.5% | $159.4M |
| Current Liabilities | $6.5M-43.5% | $11.5M+18.1% | $9.8M-15.1% | $11.5M+465.5% | $2.0M-70.4% | $6.9M-16.1% | $8.2M+5.2% | $7.8M |
| Long-Term Debt | $9.7M-51.5% | $20.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $3.8M+133.7% | -$11.3M-199.5% | $11.4M-14.4% | $13.3M+112.1% | -$109.9M-7.6% | -$102.1M-6.7% | -$95.7M-8.0% | -$88.6M |
| Retained Earnings | -$226.0M-16.4% | -$194.1M-36.5% | -$142.2M-6.7% | -$133.3M+48.4% | -$258.5M-141.6% | -$107.0M+56.8% | -$247.5M-3.8% | -$238.5M |
ELTX Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$11.1M-26.8% | -$8.7M+11.6% | -$9.9M-90.8% | -$5.2M+36.3% | -$8.1M-11.9% | -$7.3M-35.1% | -$5.4M-187.8% | $6.1M |
| Capital Expenditures | $0-100.0% | $45K | $0-100.0% | $45K+164.7% | $17K-82.1% | $95K | $0-100.0% | $559K |
| Free Cash Flow | -$11.1M-26.1% | -$8.8M+11.2% | -$9.9M-89.2% | -$5.2M+35.9% | -$8.2M-10.6% | -$7.4M-36.9% | -$5.4M-196.6% | $5.6M |
| Investing Cash Flow | $0+100.0% | -$45K | $0+100.0% | -$45K-164.7% | -$17K+82.1% | -$95K | $0+100.0% | -$559K |
| Financing Cash Flow | $9.6M+4116.7% | $227K-96.8% | $7.0M+11568.3% | $60K-99.4% | $10.0M-10.2% | $11.2M+27.3% | $8.8M+596.2% | $1.3M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $0 | $0 | $0 | N/A | $0 | $0 | N/A |
ELTX Financial Ratios
| Metric | Q3'25 | Q3'24 | Q4'23 | Q3'23 | Q1'23 | Q4'22 | Q3'22 | Q2'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -954.4% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1117.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -35.6%+13.4pp | -49.1% | N/A | -34.4%-15.2pp | -19.2%+10.1pp | -29.3%-17.6pp | -11.7%-1.4pp | -10.3% |
| Current Ratio | 3.29+1.5 | 1.80+0.1 | 1.68-0.1 | 1.74-18.3 | 20.00+18.4 | 1.56-5.4 | 6.93-1.5 | 8.47 |
| Debt-to-Equity | 2.55+4.3 | -1.77-3.2 | 1.39+0.1 | 1.33+2.7 | -1.38-0.2 | -1.22+0.4 | -1.64+0.2 | -1.80 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 854.1% |
Note: Shareholder equity is negative (-$11.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Elicio Therapeutics, Inc. profitable?
No, Elicio Therapeutics, Inc. (ELTX) reported a net income of -$51.9M in fiscal year 2024.
What is Elicio Therapeutics, Inc.'s earnings per share (EPS)?
Elicio Therapeutics, Inc. (ELTX) reported diluted earnings per share of $-4.25 for fiscal year 2024. This represents a 38.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Elicio Therapeutics, Inc.'s EBITDA?
Elicio Therapeutics, Inc. (ELTX) had EBITDA of -$44.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Elicio Therapeutics, Inc. have?
As of fiscal year 2024, Elicio Therapeutics, Inc. (ELTX) had $17.6M in cash and equivalents against $20.0M in long-term debt.
What is Elicio Therapeutics, Inc.'s free cash flow?
Elicio Therapeutics, Inc. (ELTX) generated -$37.2M in free cash flow during fiscal year 2024. This represents a -13.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Elicio Therapeutics, Inc.'s operating cash flow?
Elicio Therapeutics, Inc. (ELTX) generated -$37.1M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Elicio Therapeutics, Inc.'s total assets?
Elicio Therapeutics, Inc. (ELTX) had $28.2M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Elicio Therapeutics, Inc.'s capital expenditures?
Elicio Therapeutics, Inc. (ELTX) invested $87K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Elicio Therapeutics, Inc. spend on research and development?
Elicio Therapeutics, Inc. (ELTX) invested $33.7M in research and development during fiscal year 2024.
How many shares does Elicio Therapeutics, Inc. have outstanding?
Elicio Therapeutics, Inc. (ELTX) had 11M shares outstanding as of fiscal year 2024.
What is Elicio Therapeutics, Inc.'s current ratio?
Elicio Therapeutics, Inc. (ELTX) had a current ratio of 1.80 as of fiscal year 2024, which is generally considered healthy.
What is Elicio Therapeutics, Inc.'s debt-to-equity ratio?
Elicio Therapeutics, Inc. (ELTX) had a debt-to-equity ratio of -1.77 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Elicio Therapeutics, Inc.'s return on assets (ROA)?
Elicio Therapeutics, Inc. (ELTX) had a return on assets of -184.2% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Elicio Therapeutics, Inc.'s cash runway?
Based on fiscal year 2024 data, Elicio Therapeutics, Inc. (ELTX) had $17.6M in cash against an annual operating cash burn of $37.1M. This gives an estimated cash runway of approximately 6 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Elicio Therapeutics, Inc.'s debt-to-equity ratio negative or unusual?
Elicio Therapeutics, Inc. (ELTX) has negative shareholder equity of -$11.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Elicio Therapeutics, Inc.'s Piotroski F-Score?
Elicio Therapeutics, Inc. (ELTX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Elicio Therapeutics, Inc.'s earnings high quality?
Elicio Therapeutics, Inc. (ELTX) has an earnings quality ratio of 0.71x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Elicio Therapeutics, Inc. cover its interest payments?
Elicio Therapeutics, Inc. (ELTX) has an interest coverage ratio of -98.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.